SynOx Therapeutics Raises $75M for Breakthrough Cancer Treatment
SynOx Therapeutics, a Dublin, Ireland and Oxford, UK-based late-stage clinical biopharmaceutical company, recently announced the closing of a significant $75m Series B financing round. This funding was co-led by prominent investors Forbion, HealthCap, and new investor Bioqube Ventures. As part of this financing, distinguished individuals such as Forbion's Dr Carlo Incerti, M.D., and Bioqube Ventures' Jon Edwards, PhD, have joined the company's Board of Directors. The primary objective of this financing is to support the generation of registrational Phase 3 clinical and CMC data for emactuzumab, the company's potentially breakthrough CSF-1(R) inhibiting monoclonal antibody (mAb) designed for the treatment of Tenosynovial Giant Cell Tumour (TGCT).
Under the leadership of Ray Barlow, who serves as Chief Executive Officer, SynOx Therapeutics is dedicated to advancing emactuzumab as a cutting-edge monoclonal antibody against CSF-1R.
This innovative treatment is specifically targeted towards managing Tenosynovial Giant Cell Tumour (TGCT) and other CSF-1 related and macrophage-driven disorders. Emactuzumab stands out as a novel, next-generation CSF-1R mAb characterized by its potentially best-in-class profile. Previous clinical trials focusing on TGCT have showcased the significant clinical activity of emactuzumab, with an impressive objective response rate (ORR) of 71%, coupled with rapid and substantial tumour reduction, sustained efficacy, and notable enhancements in functional abilities. Moreover, the safety profile and tolerability of emactuzumab have been found to be favorable in these studies.
A critical milestone for SynOx Therapeutics is the initiation of a Phase 3 trial called TANGENT, which aims to evaluate the efficacy and safety of emactuzumab in patients suffering from localized and diffuse TGCT. Through continued research and clinical development efforts, the company is committed to advancing emactuzumab towards regulatory approval, with the ultimate goal of providing a transformative treatment option for individuals affected by TGCT and related conditions. The successful completion of the Series B financing represents a significant advancement in SynOx Therapeutics' mission to address unmet medical needs and deliver innovative therapies to patients in need.
They've invested in SynOx Therapeutics
Get to know these Healthtech investors
Click here for a full list of 7,526+ startup investors in the UK